compani
rivet creat sharehold
valu pt
volume-driven growth margin expans target rais
rais sales/ep
pharma sale growth compound-annual-growth-rate driven diversifi
pain emgal immunolog taltz sale
underappreci nilex oppi lli new product account
sale reiter buy/rais pt
ep support dcf
invest commun meet elev bar industri
weve privileg particip mani invest commun
meet insid warner lambert outsid industri analyst
see elev bar industri enter one best
top/bottom line compound-annual-growth-rate best group appear durabl especi
nilex opportun quantifi importantli drive
global volum asset improv product meticul
remov develop cycl impli npv
portfolio asset valuabl capit alloc intend
divest remain ownership elanco rate within
year ipo tax-effici transact also
reward sharehold dividend increas share repo
busi develop front look continu make progress
oncolog reiter buy/rais pt ep
rais sales/ep lli midpt
rais sales/ep
lli midpoint street est
revenu rais driven higher trulic emgal forteo
margin partial off-set higher interest/oth expens result
ep prior believ street underestim
robust growth trulic driven primari care physician use base
benefit once-weekli dose addit trulic taltz basaglar
jardianc verzenio cyramza olumi lartruvo emgal account
tr target
compani
total top-lin remain track launch new product
launch year intend launch two new product remain prod
pipelin sale street estim see exhibit
rais minimum revenu compound-annual-growth-rate assumpt pharma busi
aim model top-lin growth vs street
 respect margin expans key area focu manag note
oper margin human pharma expect surpass base midpt
vs
lli organ undergo transform support goal creat medicin
either first-in-class best-in-class think emgal exampl drug despit
third enter crowd cgrp space uniqu differenti posit best-in-class
perform discoveri decreas time target identif clinic test
ii use extern innov enrich pipelin instanc announc four pre-
clinic transact lead invest day dicerna pharma buy edward nash ac
immun privat hydra bioscienc privat rate develop
reduc averag time first human dose commerci launch year
view clinic trial design optim next frontier achiev
 cycl time reduct importantli also made dramat improv phase
success rate rate trend brought improv
target valid patient popul select molecul optim robust data phase
design lli global busi align four five fastest grow therapeut area
util value-bas contract henc clinic trial protocol collect data asset
ensur demonstr cost-benefit analysi posit drug commerci success
aim overtak novo nvo nr diabet player
think track doubl diabet revenu
long-term growth driven launch asset trulic transform market
gener global growth share trulic highest adher rate
diabet medic esp vs oral refil rate pt motiv weight loss
 get target think there tremend oppi trulic grow global share
expand class view rewind result precedent-set see note
full data present ada june san francisco model trulic sale
street lly/boehring ingelheim privat jardianc continu domin
class us share sourc growth could come heart failur
chronic kidney diseas cardiovascular diseas label expans account
us oral diabet market impli signific room growth market leader
model jardianc allianc revenu vs street lli innov pipelin asset
tirzepatid co-agonist intranas glucagon easier deliv
xeri pharma rate glucagon inject ultra-rapid insulin lispro lli
tirzepatid could disrupt asset diabet arena profil back
best-in-class efficaci trial see note initi surpass clinic program
 also commit initi studi obes studi nash
intranas glucagon review us/eu hypoglycemia expect mover adv
ultra-rapid insulin lispro regulatori submiss plan
immunolog taltz/olumi nilex oppi mirikizumab
think street underappreci new indications/label expans nilex opportun
taltz olumi model taltz olumi combin sale approxim
street taltz psoriasi market share doubl last two
year us provid addit room growth taltz earli launch
expect get boost spirit studi show superior abbvi
coast-v coast-w trial see note wait read-out non-radiograph axspa
olumi uptak rheumatoid arthriti ra underwhelm us due
dose get approv see eu japan market provid signific revenu
opportun moreov olumi broad clinic develop effort atop dermat ad
page
compani
seven on-going system lupu erythematosu sle two on-going alopecia aeriata
aa seamless on-going top-lin data aa ad sle expect
respect lastli move mirikizumab trial pso present
impress pso data aad march includ pasi score
dose vs placebo expect mirikizumab ulcer coliti top-
line data also plan initi crohn diseas studi conting result
oncolog need addit bd activ enrich pipelin
lli verzenio cyramza erbitux alimta lartruvo pegilodecakin contribut
compound-annual-growth-rate wherea oncolog market grow much faster low-teen compound-annual-growth-rate
segment immuno-oncolog pois compound-annual-growth-rate nevertheless verzenio abemaciclib
shown earli success market nbrx share bullish futur
verzenio growth mbc adjuv breast cancer high-risk us
pt set recent meet manag see note acknowledg
focus in-licens collabor secur next wave innov complet
deal ytd includ acquisit aurka click note armo click
 collabor agreement privat look pegilodecakin pegyl
sequoia data pancreat cancer primari complet top-lin
data trial non-smal cell lung cancer nsclc
model late launch risk-adj pegilodecakin sale vs street
pain add leg growth tanezumab wild card
lli pain franchis repres fourth leg growth busi enter
commerci phase launch emgal view emgal differenti
label prevent treatment migrain vs cgrp label includ faster onset
efficaci data result function measur emgal earlier onset effect
induct dose conveni inject devic comprehens label bode well
garner first-in-class share despit third-in-class launch moreov think emagilti launch
episod cluster headach halo effect brand migrain prophylaxi commerci
see note titl cgrp show efficaci benefit debilit cluster
headach file lasmiditan nda treatment acut migrain expect
fda action note deep-div see note titl colucid deal add
innov acut migrain asset pain segment quiver view lasmiditan novel compound
differenti moa posit take share annual triptan trx acut
migrain set cautious optimist tanezumab anti-nerv growth factor ngf
develop osteoarthr chronic lower back pain clbp collabor
hold combin oa clbp repres patient us alon /lli expect
three remain trial tanezumab oa oa efficaci long-term safeti
 chronic low back pain tango read earli phase
oa trial tanezumab met three co-primari endpoint show rapidli progress osteoarthr
ropa tanezumab treat patient vs placebo arm view tanezumab high-
risk/reward opportun pain market
alzheim asset multipl read-out
alzheim diseas high-risk/high-reward area continu approach novel
therapeut target notabl alzheim compound includ lli antibodi tau deposit
monoclon antibodi oral compound act dopamin receptor
enhanc lli monotherapi treatment arm continu phase studi trailblazer-
alz treatment earli symptomat alzheim diseas lli also phase
earli symptomat ad patient current enrol parkinson diseas dementia
trial presenc result expect given lli effort alzheim
arena last year think uniqu posit nuanc understand
alzheim biolog patient select henc think ideal posit enrol right
patient alzheim trial enhanc probabl success
page
compani
page
rang rang rang rang rang rang rang rang midpointstrh estimatesconsensu gross incomenot providednot providednot providednot providednot providednot providednot providednot incom incomenot providednot providednot providednot providednot providednot providednot providednot share countnot providednot providednot providednot providednot providednot providednot providednot flownot providednot providednot providednot providednot providednot providednot providednot yellow indic chang rang rang midpointstrh estimatesconsensu digit growth due fx new product sale gross incomenot providednot incom interest exp higher debt level lower plan gain invest tax incomenot providednot nci elanco anim healthgaap share flownot providednot eli lilli compani
page
millionscurrentprior chg chg total incom non-oper incom incom interest incom outstand analysiscurrentprior chg chg bp product gross changecurrentcurr chg chg bp net product incom incom millionscurrentprior chg chg total incom non-oper incom incom interest incom outstand analysiscurrentprior chg chg bp product gross changecurrentcurr chg chg bp net product incom incom eli lilli compani
exhibit estim strh vs consensu
exhibit lli select nme nilex opportun total address market size
year launch
page
vs strh vs vs areabrand namegener namemechan actionind line extensiontot address market size launch yearolumiantbaricitinibjanu kinas jak inhibitoratop dermat baricitinibjanu kinas jak inhibitoralopecia areata kinas jak inhibitorsystem lupu erythematosu olumi inhibitorpsoriat arthriti inhibitoraxi spondyloarthr axspa taltz cv cotransport failur glucagonpeptid growth factor ngf osteoarthr chronic lower back pain gene-rel peptid cgrp inhibitorprophylaxi treatment chronic/ episod receptor agonistacut eli lilli compani
page
datecompanyproductev categoryev sub-typ filingsubmit eu emgal episod cluster headacheearli releasephas data verzenio breast cancer patient actionexpect fda approv base os completionreadout second cv outcom studi filingsubmit empagliflozin linagliptin metformin xr type initiationphas trial initi chronic kidney diseas releasephas trial durat osteoarthr oa hip releasephas long-term safeti trial osteoarthr oa hip releasephas tango trial chronic lower back releas data relay studi cyramza roch tarceva egfr submiss trulic base rewind cv outcom releasephas program top-line data atop dermat start releasephas top-line data crohn diseas phase initi conting phase regulatori applic type diabet lispro regulatoryfilingsubmit regulatori applic ultra-rapid lispro initiationphas initi initiationphas initi nonalcohol steatohepat elanelanco anim healthcorporatedemergerexpect full separ one year anniversari ipo sept releasephas overal surviv read-out soft tissu initiationphas initi renal cell carcinoma alloster modulatorclinicaldata releasephas data mild-to-moder parkinson diseas antibodyclinicaldata releasephas read-out releasephas read-out prexasertib kinas inhibitorclinicaldata releasephas read-out aurora kinas inhibitormar sotagliflozin regulatoryfda actionpdufa zynquista sotagliflozin dual inhibitor treatment type analysisheart failur trial emperor reduced/preserv trial interim analysi may completionprimari complet heart failur trial emperial-reduced/preserv trial walk testjun completionpre-clin trial identifi biomark predict dev alzheim diseasejun releaseada full result trulic rewind cv outcom glucagonregulatoryfda/ema actionexpect fda/ema approv intranas glucagon cyramzaregulatoryema/jpmda actionexpect ema/jpmda approv base os datajul completionphas primari complet galunisertib xtandi releasephas top-lin result non-radiograph axial actionexpect fda approv type diabet jul completionphas head-to-head studi result taltz vs tremfya moderate-to-sever plaqu psoriasissep clinicaltri completionphas announc trial actionexpect fda approv inclus carmelina cv outcom data tradjenta actionexpect fda approv lasmiditan acut migrainel releasephas top-line result nsclc combo keytruda releasephas top-line result nsclc combo opdivo actionexpect fda approv taltz radiograph axial actionexpect fda approv emgal cluster filingsubmit nda tanezumab releasepoc arrow trial nv cosentyx vs tremfya pso resist treatment stelara ivcommercialu launchestim launch lasmiditan iv us marketapr completionphas studi patient associ brain releasephas top-line result sequoia pancreat combo releaseoveral surviv os data antibodyclinicaldata releasephas data earli symptomat alzheim diseas releasephas top-line data alopecia releasephas top-line data psoriasi eli lilli compani
page
abemaciclib synjardi glyxambi insulin olumi compani
page
galcanezumab strh- in-lin pipelin compani
exhibit incom statement
page
restat product incom non-oper incom incom interest incom net ep outstand analysisgross changenet product incom incom metricspric eli lilli compani
exhibit consolid balanc sheet
page
current plant equip borrow current portion lt tax current incom medic benefit non-curr paid-in benefit comprehens stock sharehold liabil sharehold eli lilli compani
exhibit statement
page
compens impair -- -- -- -- -- -- -- -- -- -- -- -- -- non-cash defer cash releas prop process common st borrow long-term long-term exchang begin end eli lilli compani
lilli lead research-bas biopharmaceut compani focus drug discoveri
clinic develop manufactur commerci pharmaceut product human
anim diseas gener sale yoy gener
us ex-u market human medicin busi includ core franchis
neurosci diabet women oncolog cardiovascular contribut
 total sale global leader diabet arena new product
trulic basaglar collabor asset jardianc tradjenta lli oncolog franchis
compris inhibitor verzenio abemaciclib alimta cyramza portrazza lartruvo
also place stake ground establish immunolog franchis
launch taltz olumi lli fourth leg emerg growth target pain market
enter commerci phase emgal derisk late-stag asset lasmiditan
tanezumab enter one best new product cycl year histori new product
rate buy base attract low-teen earn growth mid/high-singl
digit volum driven sale growth commit expand oper margin tight
cost manag new product cycl unfold
model assum doubl diabet franchis level
jardianc basaglar trulic offset declin establish product
humalog humulin expect jardianc take materi share market
older gener therapi owe cardiovascular-benefit also expect grow oncolog
franchis support verzenio alimta cyramza portrazza lartruvo verzenio third-to-market
inhibitor segment multipl use breast cancer market
immunolog taltz olumi baricitinib expect contribut sale
think olumi long-term growth benefit expand asset commerci reach much
possibl geograph eu/japan label expans atop dermat system lupu
erythematosu psoriat arthriti taltz posit captur mid-teen percentag psoriasi
treat patient popul next five year lastli lli emerg pain franchis repres
fourth leg growth differenti late-stag asset significantli derisk lasmiditan
tanezumab recent launch emgal emgal robust efficaci placebo-lik safeti posit
take materi share cgrp market lasmiditan first-in-class molecul
offer cardiovascular safeti advantag acut migrain standard-of-car triptan
oper leverag margin expans central thesi compani contain fix
cost grow revenu base next five year
valuat risk
valuat pt assum trade ep reflect premium
us pharma major multipl think premium group justifi given lli
innovation-driven diversifi global volume-driven sale growth oper leverag cash flow
gener price target support discount cash flow dcf intrins valu
risk thesi revolv around clinic regulatori setback commerci execut
global price pressur face patent expir ciali forteo alimta
competit pressur trulic nvo ozemp partli mitig rewind outcom
studi humalog biosimilar insulin lispro expect off-set product launch
compani mention note
compani buy john bori
page
compani
rate
novo nordisk nvo rate
elanco rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
